TScan Therapeutics Decline Means Insider Profits Down To US$54k [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
After accounting for the recent loss, the US$167.9k worth of shares they purchased is now worth US$222.0k, suggesting a good return on their investment. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. Check out our latest analysis for TScan Therapeutics TScan Therapeutics Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by insider Timothy Barberich for US$142k worth of shares, at about US$4.97 per share. We do like to see buying, but this purchase was made at well below the current price of US$6.50. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price. While TScan Therapeutics insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last ye
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics Announces Updates to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics Announces Updates to its Board of DirectorsGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
TCRX
Earnings
- 5/13/24 - Miss
TCRX
Sec Filings
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- TCRX's page on the SEC website